<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine whether low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> (LMWH) plus low-dose aspirin (LDA) is comparable in efficacy and safety to unfractionated <z:chebi fb="5" ids="28304">heparin</z:chebi> (UFH) plus LDA in the management of pregnant women with a history of recurrent <z:hpo ids='HP_0005268'>spontaneous abortion</z:hpo> secondary to <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: In a randomized prospective study, 60 women with a history of 3 or more consecutive <z:hpo ids='HP_0005268'>spontaneous abortions</z:hpo> and positive <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> were assigned in equal numbers to receive either UFH (5000 units, twice daily) plus LDA, or LMWH (enoxaparin 40 mg, once daily) plus LDA as soon as pregnancy was diagnosed </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Twenty-four women in the LMWH group (80%) and 20 women in the UFH group (66.67%) delivered a viable infant (P = 0.243) </plain></SENT>
<SENT sid="3" pm="."><plain>There were no significant differences in <z:e sem="disease" ids="C0032962" disease_type="Disease or Syndrome" abbrv="">pregnancy complications</z:e> or neonatal morbidity between the 2 groups </plain></SENT>
<SENT sid="4" pm="."><plain>There were no incidences of excessive <z:mp ids='MP_0001914'>bleeding</z:mp>, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, or <z:e sem="disease" ids="C0521170" disease_type="Disease or Syndrome" abbrv="">osteoporotic fractures</z:e> in either group </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: LMWH plus LDA was successfully used as an alternative to UFH plus LDA in the management of <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent abortion</z:e> secondary to APS </plain></SENT>
<SENT sid="6" pm="."><plain>The results highlight the need for a larger randomized controlled trial to determine whether LMWH plus LDA should be the treatment of choice for <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent abortion</z:e> secondary to APS </plain></SENT>
<SENT sid="7" pm="."><plain>Clinicaltrials.gov NCT01051778 </plain></SENT>
</text></document>